Comparative Pharmacology
Head-to-head clinical analysis: KENALOG 80 versus TRIESENCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENALOG 80 versus TRIESENCE.
KENALOG-80 vs TRIESENCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triamcinolone acetonide is a synthetic corticosteroid with potent anti-inflammatory, immunosuppressive, and anti-proliferative effects. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of phospholipase A2, which reduces prostaglandin and leukotriene synthesis. It also suppresses cytokine production and immune cell migration.
Corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating cytokine production.
60 mg (1.5 mL) intramuscularly (deep IM) as a single dose for allergic/ inflammatory conditions; intra-articular or soft tissue injection: 10-40 mg for large joints, 5-25 mg for medium joints, 2.5-10 mg for small joints; intralesional: up to 1 mg per injection site, repeated as needed.
1 to 4 mg (0.025 to 0.1 mL of 40 mg/mL suspension) intravitreal injection once.
None Documented
None Documented
Terminal elimination half-life: 2–4 hours for triamcinolone acetonide; prolonged in hepatic impairment (up to 6–8 hours).
Approximately 3.3 hours for triamcinolone acetonide; with intravitreal administration, detectable levels persist for weeks to months.
Primarily hepatic metabolism followed by renal excretion of inactive metabolites; less than 5% excreted unchanged in urine, with minor biliary/fecal elimination (<2%).
Primarily hepatic metabolism; renal excretion of metabolites (<5% unchanged). Biliary/fecal elimination accounts for minimal clearance.
Category C
Category C
Corticosteroid
Corticosteroid